Treatment of Helicobacter pylori Is Not Associated With Future Clostridium difficile Infection

Helicobacter Pylori

Clostridium difficile-associated disease and Helicobacter pylori seroprevalence: A case-control study

Helicobacter.

Muhsen K, Na'amnih W, Adler A, Carmeli Y, Cohen D

doi: 10.1111/hel.12668.

Colonoscopy

The association between Helicobacter pylori infection and the risk of advanced colorectal neoplasia may differ according to age and cigarette smoking

Helicobacter.

Park H, Park JJ, Park YM, Baik SJ, Lee HJ, Jung DH, Kim JH, Youn YH, Park H

doi: 10.1111/hel.12477.

Helicobacter Pylori

Pylera® plus ranitidine vs Pylera® plus esomeprazole in first-line treatment of Helicobacter pylori infection: Two pilot studies

Helicobacter.

Ciccaglione AF, Cellini L, Marzio L

doi: 10.1111/hel.12606.

Helicobacter Pylori

Helicobacter pylori-associated peptic ulcer disease: A retrospective analysis of post-treatment testing practices

Helicobacter.

Feder R, Posner S, Qin Y, Zheng J, Chow SC, Garman KS

doi: 10.1111/hel.12540.

Helicobacter Pylori

Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota

J Gastroenterol Hepatol.

Liou JM, Lee YC, Wu MS

doi: 10.1111/jgh.14992.

RECOMMENDED

Helicobacter Pylori

Review: Treatment of Helicobacter pylori Infection 2019

Helicobacter.

O'Connor A, Liou JM, Gisbert JP, O'Morain C

doi: 10.1111/hel.12640.

Helicobacter Pylori

Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes

Am J Gastroenterol.

Boltin D, Levi Z, Gingold-Belfer R, Gabay H, Shochat T, Niv Y, Dickman R, Dotan I, Birkenfeld S

doi: 10.14309/ajg.

RECOMMENDED

Helicobacter Pylori

Review: Epidemiology of Helicobacter pylori infection

Helicobacter.

Leja M, Grinberga-Derica I, Bilgilier C, Steininger C

doi: 10.1111/hel.12635.

Inflammatory Bowel Disease

Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)

Eur J Clin Microbiol Infect Dis.

Vehreschild MJGT, Taori S, Goldenberg SD, Thalhammer F, Bouza E, van Oene J, Wetherill G, Georgopali A

doi: 10.1007/s10096-018-3344-1.

Related content

Clostridium difficile-associated disease and Helicobacter pylori seroprevalence: A case-control study

The association between Helicobacter pylori infection and the risk of advanced colorectal neoplasia may differ according to age and cigarette smoking

Pylera® plus ranitidine vs Pylera® plus esomeprazole in first-line treatment of Helicobacter pylori infection: Two pilot studies

Helicobacter pylori-associated peptic ulcer disease: A retrospective analysis of post-treatment testing practices

Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota

Review: Treatment of Helicobacter pylori Infection 2019

Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes

Review: Epidemiology of Helicobacter pylori infection

Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)